Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BoI Official Confident of Biotechnology Future (Thailand)

This article was originally published in PharmAsia News

Executive Summary

Ajarin Pattanapanchai, executive investment adviser for Thailand's Board of Investment, says the emergence of a number of multinational and local companies in the biotechnology business underlines the success of efforts to grow its biotechnology industry. Though Thailand is behind Japan, Singapore, Korea, Malaysia, China, and India in promoting biotechnology, Pattanapanchai points out that the industry depends on personnel with exceptional skills, providing Thailand with an opportunity to catch up by focusing on that area. ''We continue developing and producing personnel from both the state and private educational institutions, especially through strong support from the National Science and Technology Development Agency,'' she says. The entry of multinationals to set up blood banks for special disease diagnosis, stem cell processing, drug production, environmental conservation, and increased productivity for agro-processing industries are all positive signs for the emerging biotech industry. (Click here for more

You may also be interested in...

Early Promise Of NextCure’s Novel IO Candidate Continues To Fade

Lead immuno-oncology asset NC318 targeting Siglec-15 showed encouraging early activity in patients refractory to PD-1/L1 inhibitors, but now Phase II plans are scuttled in lung and ovarian cancers.

With Pataday Extra Strength, Alcon Eyes Consumers Looking For OTC 24-Hour Eye Allergy Remedy

Pataday Once Daily Relief Extra Strength is the same formulation as Novartis' Rx Pazeo. It will be the first OTC eye drop indicated for allergy itch with 24-hour efficacy, available online in September and through retailers in early 2021.

Deal Watch: Merck's Busy Stretch Includes Collaborations With Dewpoint, Zymeworks

Bristol makes its own deal with Celgene ally Dragonfly, while Gilead ends virology partnerships with Durect and Precision BioSciences.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts